

*Biopharmaceutical Contract Fill-and-Finish:
Best Practices Study 2018*

Table of Contents

Presented by

HighTech Business Decisions

3150 Almaden Expressway, Suite 222, San Jose, CA 95118

Tel: (408) 978-1035 Fax: (408) 978-8925

www.hightechdecisions.com

January 2018

Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2018

TABLE OF CONTENTS

Chapter 1:	EXECUTIVE SUMMARY	
	1.1 Introduction	1-1
	1.2 Market Overview	1-2
	1.2.1 Introduction	1-2
	1.2.2 Industry Drivers	1-3
	1.2.3 Market Size	1-4
	1.3 Summary of Customer Needs	1-5
	1.3.1 Products	1-5
	1.3.2 Outsourcing Strategies	1-7
	1.3.3 Outsourcing Budgets	1-9
	1.4 Summary of Fill-and-Finish Contractors' Capabilities	1-10
	1.4.1 Dosage Forms	1-10
	1.4.2 Capacity Changes	1-11
	1.4.3 Industry and Company Growth Rates	1-12
	1.4.4 Contracting Business by Product Type	1-13
	1.5 Industry Trends and Observations	1-14
<hr/>		
Chapter 2:	METHODOLOGY, DEFINITIONS, AND ACRONYMS	
	2.1 Research Objectives	2-1
	2.2 Research Methodology	2-2
	2.3 Definition of Parenteral Fill-and-Finish Manufacturing	2-4
	2.4 Box-and-Whiskers Plot Definition	2-4
	2.5 Acronyms	2-5
<hr/>		
Chapter 3:	FILL-AND-FINISH CONTRACT MANUFACTURING: MARKET OVERVIEW	
	3.1 Introduction	3-1
	3.2 Suppliers: The Fill-and-Finish Contract Manufacturers	3-2
	3.2.1 Types of Fill-and-Finish Contract Companies	3-2
	3.2.2 Fill-and-Finish Contract Manufacturing Companies	3-3
	3.2.3 Organizational Changes in the Industry	3-4
	3.2.4 Dosage Forms and Services	3-6
	3.2.5 Fill-and-Finish CMOs' Capacities	3-7

Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2018

TABLE OF CONTENTS (continued)

Chapter 3:	3.3 The Customers: Pharmaceutical and Biotechnology Companies	3-8
	3.3.1 <i>Customers' Products</i>	3-8
	3.3.2 <i>Outsourced Fill-and-Finish by Dosage Form</i>	3-9
	3.3.3 <i>Customers' Future Outsourcing Expectations</i>	3-10
	3.3.4 <i>Outsourcing Needs</i>	3-11
	3.4 Market Capacity	3-12
	3.5 Market Size	3-13
	3.5.1 <i>Estimates of Market Size</i>	3-13
	3.5.2 <i>Market Size by Dosage Form and Service Categories</i>	3-13
	3.6 Market Growth Forecasts	3-14
	3.7 Trends in the Fill-and-Finish Contract Manufacturing Market	3-16
	3.7.1 <i>Industry Challenges</i>	3-16
	3.7.2 <i>Outsourcing Trend of One-Stop-Shop versus Single-Service CMOs</i>	3-16
<hr/>		
Chapter 4:	PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES: CLIENT ANALYSIS	
	4.1 Introduction	4-1
	4.1.1 <i>Respondent Titles and Locations</i>	4-1
	4.1.2 <i>In-House Manufacturing Sites</i>	4-3
	4.1.3 <i>Recombinant Large-Molecule Drug Products on Market</i>	4-5
	4.2 Manufacturing Demand	4-5
	4.2.1 <i>Manufacturing Needs</i>	4-5
	4.2.2 <i>Dosage Forms</i>	4-13
	4.2.3 <i>Clinical and Commercial Products</i>	4-15
	4.3 Device Delivery Technologies	4-19
	4.3.1 <i>Planned Format for Drug Product Launch</i>	4-19
	4.3.2 <i>Importance of Device Development to Drug Product Portfolio</i>	4-21
	4.3.3 <i>Container-Closure System Development and Qualification</i>	4-25
	4.3.4 <i>Formulation Development and Compatibility</i>	4-30
	4.4 Manufacturing Technologies	4-37
	4.4.1 <i>Development of Fill-and-Finish Process</i>	4-37
	4.4.2 <i>New Fill-and-Finish Technologies</i>	4-43
	4.4.3 <i>Special Handling Requirements</i>	4-47
	4.4.4 <i>Yield Loss</i>	4-51

Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2018

TABLE OF CONTENTS (continued)

Chapter 4:	4.5 Outsourcing Strategies	4-56
	<i>4.5.1 Current In-House Filling Capacity and Outsourcing Strategy</i>	4-56
	<i>4.5.2 Changes to In-House Filling Capacity</i>	4-59
	<i>4.5.3 Fill-and-Finish Importance to Drug Product Portfolio</i>	4-61
	<i>4.5.4 Focus Areas of Fill-and-Finish Outsourcing Over Next 5 Years</i>	4-65
	4.6 Outsourcing Needs	4-69
	<i>4.6.1 Outsourced Services</i>	4-69
	<i>4.6.2 Areas Underserved by Fill-and-Finish CMOs</i>	4-71
	<i>4.6.3 Key Challenges a Fill-and-Finish CMO Can Help Alleviate</i>	4-78
	4.7 Contractor Selection	4-82
	<i>4.7.1 Preference for Integrated Drug Substance and Drug Product CMO</i>	4-82
	<i>4.7.2 Top Attributes for CMO Selection</i>	4-88
	<i>4.7.3 Attributes That Would Prevent CMO Selection</i>	4-91
	<i>4.7.4 Reasons for Leaving Current CMO</i>	4-95
	<i>4.7.5 Outsourcing Decision Influenced by CMO Capital Investment</i>	4-99
	<i>4.7.6 Regional Outsourcing Preference</i>	4-104
	4.8 Contractor Pricing	4-109
	<i>4.8.1 Change in CMO Pricing for Fill-and-Finish Services</i>	4-109
	<i>4.8.2 Price Models Used</i>	4-111
	4.9 Outsourced Spending	4-114
	<i>4.9.1 Prices Paid to Fill-and-Finish CMOs</i>	4-114
	<i>4.9.2 Outsourcing Budget</i>	4-120
	<i>4.9.3 Outsourcing Budget by Service Category</i>	4-122
	4.10 Contractor Relationships	4-126
	<i>4.10.1 Troubleshooting Capabilities of CMOs</i>	4-126
	<i>4.10.2 Top Issues of Contractors Meeting Expectations</i>	4-133
	<i>4.10.3 Preferred Contractors</i>	4-138
	4.11 Future Trends and Expectations	4-140
	<i>4.11.1 Top Concerns Regarding Contract Fill-and-Finish Industry</i>	4-140
	<i>4.11.2 Outsourcing Trends for One-Stop-Shop CMOs versus Single-Service CMOs</i>	4-145

Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2018

TABLE OF CONTENTS (continued)

Chapter 5:	FILL-AND-FINISH CONTRACT MANUFACTURERS	
5.1	Introduction	5-1
5.1.1	<i>Respondents' Titles and Experience</i>	5-1
5.1.2	<i>Company Locations</i>	5-3
5.1.3	<i>Regulatory Approval Status</i>	5-3
5.1.4	<i>Acquisitions and Organizational Changes</i>	5-4
5.2	Capacity	5-7
5.2.1	<i>Dosage Forms</i>	5-7
5.2.2	<i>Current Capacity for Fill-and-Finish</i>	5-8
5.2.3	<i>Current Capacity for Lyophilization</i>	5-9
5.2.4	<i>Capacity Changes</i>	5-10
5.3	Manufacturing Practices	5-12
5.3.1	<i>Contracting Business by Product Type</i>	5-12
5.3.2	<i>Current and Future Capacity Utilization</i>	5-14
5.3.3	<i>Average Batch Size and Batches Ran per Fill Line in 2017</i>	5-16
5.3.4	<i>Drug Product Development Support</i>	5-20
5.4	Manufacturing Activities	5-22
5.4.1	<i>Fill versus Finish Activity Outsourcing</i>	5-22
5.4.2	<i>Operational Challenges</i>	5-25
5.4.3	<i>Average Yield Loss</i>	5-28
5.5	Manufacturing Technologies	5-30
5.5.1	<i>Technology Impacts on Operations</i>	5-30
5.5.2	<i>Importance of Device Development</i>	5-33
5.5.3	<i>Investments in Fill-and-Finish Capabilities Over Next 5 Years</i>	5-35
5.5.4	<i>Investments in Specialized Equipment</i>	5-38
5.5.5	<i>New Technologies or Capabilities Needed</i>	5-40
5.6	Pricing	5-42
5.6.1	<i>Change in CMO Pricing for Fill-and-Finish Services</i>	5-42
5.6.2	<i>Price Structures for Fill-and-Finish</i>	5-45
5.6.3	<i>Batch Pricing</i>	5-48
5.6.4	<i>Gross Profit Margin</i>	5-50
5.7	Customer Relationships	5-51
5.7.1	<i>How CMOs Differentiate Themselves</i>	5-51
5.7.2	<i>Structure of Multi-Molecule Agreements</i>	5-54
5.7.3	<i>Liability Limits</i>	5-57
5.7.4	<i>Liability Limits for High-Cost API</i>	5-59
5.7.5	<i>Challenges of Managing Client Relationship</i>	5-60

Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2018

TABLE OF CONTENTS (continued)

Chapter 5:	5.8 Fill-and-Finish Industry Growth and Size	5-63
	<i>5.8.1 Opportunities for Growth in the Fill-and-Finish Industry</i>	5-63
	<i>5.8.2 Industry and Company Growth Rates</i>	5-65
	<i>5.8.3 Current and Expected Revenue Categories</i>	5-67
	<i>5.8.4 Revenues from Clinical Phases</i>	5-69
	<i>5.8.5 Revenues from Industry Segments</i>	5-71
	<i>5.8.6 Revenues from World Regions</i>	5-73
	5.9 Challenges and Future Trends for F&F Manufacturing	5-74
	<i>5.9.1 Most Significant Challenges/Threats</i>	5-74
	<i>5.9.2 Outsourcing Trends for One-Stop-Shop CMOs versus Single-Service CMOs</i>	5-78

Appendix A: Write-Ups of Interviews with 27 Pharmaceutical and Biotechnology Company BioManufacturing Directors Worldwide, Unnamed and Edited for Confidentiality

Appendix B: Directory of Biopharmaceutical Fill-and-Finish Contract Manufacturers

Appendix C: Interview Guide for Pharmaceutical and Biotechnology Company Respondents

Appendix D: Interview Guide for Biopharmaceutical Fill-and-Finish Contract Manufacturers

Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2018

LIST OF TABLES

Chapter 1

1.3-1	Respondents' Production Capability by Segment	1-7
1.3-2	Gaps and Solutions for In-House Fill-and-Finish Production Capability	1-8
1.4-1	Capacity Expansions	1-12
1.5-1	Industry Trends and Challenges	1-15

Chapter 2

2.2-1	Market Research Steps	2-2
2.5-1	Acronyms	2-5

Chapter 3

3.2-1	User Respondents' Fill-and-Finish Contract Manufacturers	3-3
3.2-2	Examples of Changes or Events in the F&F Industry: Past Two Years	3-5
3.2-3	CMO Revenue Mix by Service Category: 2018	3-7
3.3-1	Estimates of Needs for Outsourced Volumes for the Respondent Group	3-12
3.4-1	Biopharmaceutical F&F Contract Manufacturing Capacity Utilization	3-12
3.5-1	Market Size by Dosage Forms in 2017: US\$	3-13
3.5-2	Market Size by Service Category in 2017: US\$	3-14

Chapter 4

4.1-1	Titles of Pharmaceutical and Biotechnology Company Respondents	4-2
4.1-2	Location of In-House Fill-and-Finish Manufacturing Sites	4-4
4.1-3	Number of Recombinant Large-Molecule Drug Products on Market	4-5
4.2-1	Respondents' Current and Expected Capacity Needs for Outsourced Product – Vials (Lyophilized)	4-6
4.2-2	Respondents' Current and Expected Capacity Needs for Outsourced Product – Vials (Not Lyophilized)	4-8
4.2-3	Respondents' Current and Expected Capacity Needs for Outsourced Products – Syringes (Lyophilized)	4-10
4.2-4	Respondents' Current and Expected Capacity Needs for Outsourced Products – Syringes (Not Lyophilized)	4-11
4.2-5	Number of Outsourced Products by Phase by Year	4-14
4.2-6	Average Outsourcing Percentage by Dosage Form	4-14
4.2-7	Number of Biopharmaceutical Products Filled by Dosage Form	4-16
4.2-8	Respondents' Biopharmaceutical Product Types by Dosage Form	4-19

Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2018

LIST OF TABLES (continued)

Chapter 4

4.3-1	Device Development Outsourced	4-23
4.3-2	Strategies for Qualifying Container-Closure System	4-26
4.3-3	Qualifying Container-Closure System	4-26
4.3-4	Formulation Development to Ensuring Compatibility	4-31
4.3-5	Approaches to Ensuring Compatibility with Fill Process	4-32
4.4-1	Approaches to Fill-and-Finish Process Development	4-37
4.4-2	Fill-and-Finish Process Development Activities	4-38
4.4-3	New Fill-and-Finish Technologies	4-44
4.4-4	Causes for Fill-and-Finish Yield Loss	4-53
4.5-1	Respondents' Production Capability by Segment	4-57
4.5-2	Gaps and Solutions for In-House Fill-and-Finish Production Capability	4-58
4.5-3	Core Technology Consideration and Impact on Outsourcing Decision	4-63
4.6-1	Outsourcing of Fill-and-Finish Related Services	4-70
4.6-2	Number of Products Currently and Planned to Outsource by Service	4-71
4.6-3	Areas Underserved by Fill-and-Finish CMOs	4-73
4.6-4	Challenges Fill-and-Finish CMOs Can Help Alleviate	4-79
4.7-1	Preference for One-Stop-Shop CMO by Company Segment	4-84
4.7-2	Top Three Attributes for CMO Selection	4-89
4.7-3	Top Three Attributes Prevent CMO Selection	4-92
4.7-4	Reasons Why Companies Would Leave Their CMO	4-96
4.7-5	Capital Investments That Will Influence Outsourcing Decisions	4-100
4.7-6	Regional Outsourcing Preferences	4-105
4.7-7	Reasons for Regional Outsourcing Preferences	4-105
4.8-1	Price Model Used for Fill-and-Finish Services by Respondent Type	4-111
4.9-1	Price Per-Batch by Dosage Form by Product Phase	4-115
4.9-2	Examples of Other Services and Material Charges	4-119
4.9-3	Fill-and-Finish Outsourcing Budgets by Respondent Type: 2018, 2020, 2023	4-121
4.9-4	Simple Average: Percentage of F&F Outsourcing Budget by Service	4-123
4.9-5	Weighted Average: Percentage of F&F Outsourcing Budget by Service	4-125
4.10-1	Reasons for CMO Troubleshooting Satisfaction Level	4-128
4.10-2	Top Issues of Fill-and-Finish Contractors Meeting Expectations	4-134
4.10-3	Respondents' Fill-and-Finish Contract Manufacturers	4-139
4.11-1	Top Concerns Regarding Contract Fill-and-Finish Industry	4-141
4.11-2	Summary of Expected Outsourcing Trends: One-Stop-Shop vs. Single-Service CMO	4-147
4.11-3	Summary of Preference for Single-Service CMOs Split by Trend	4-148

Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2018

LIST OF TABLES (continued)

Chapter 5

5.1-1	Titles of Fill-and-Finish Contractor Respondents	5-1
5.1-2	Fill-and-Finish Contractors: Headquarter Locations	5-3
5.1-3	Regulatory Agency Approvals	5-4
5.1-4	Examples of Company Changes in the F&F Industry: Past Two Years	5-5
5.1-5	Organizational Changes Over Last Two Years	5-7
5.2-1	Average Batch Size per Fill Line and per Contractor	5-9
5.2-2	Fill Capacity by Batch Size at Respondents' Facilities in 2017	5-9
5.2-3	Lyophilizer Capacity by Shelf Space at Respondents' Facilities in 2017	5-10
5.2-4	Capacity Expansions	5-12
5.3-1	Breakout of Contracting Business by Product Type: 2018 and 2020	5-13
5.3-2	Average Capacity Utilization Rates	5-15
5.3-3	Number of Batches Ran per Fill Line in 2017	5-17
5.3-4	Batch Size Ran by Fill Line in 2017	5-19
5.3-5	Drug Product Development Support Activities	5-21
5.4-1	Limited Finish Capabilities	5-24
5.4-2	Operational Challenges	5-26
5.4-3	Sources of Product Yield Loss	5-29
5.5-1	Technology Impacts on Fill-and-Finish Operations	5-31
5.5-2	Investment in Device Development	5-34
5.5-3	Fill-and-Finish Investments in Next 5 Years	5-37
5.5-4	Specialized Equipment Investments	5-39
5.6-1	Pricing Methods for Clinical and Commercial Phase	5-46
5.6-2	Gross Profit Margin	5-50
5.7-1	Factors CMOs Use to Differentiate Themselves	5-52
5.7-2	Multi-Molecule Agreement Value-Adds	5-55
5.7-3	Client Relationship Challenges	5-61
5.8-1	Opportunities for Growth in the Fill-and-Finish Industry	5-64
5.8-2	Annual Growth Rates: Industry Estimate versus Company Forecast	5-66
5.8-3	Expected Revenue Mix by Service Category: 2018	5-67
5.8-4	Expected Revenue Change by Service Category: 2018 to 2020	5-69
5.8-5	Expected Revenue by Product Phase: 2018	5-70
5.8-6	Expected Revenue Change by Product Phase: 2018 to 2020	5-71
5.8-7	Expected Revenue Contribution by Customer Type	5-72
5.8-8	Expected Revenue from World Regions	5-73
5.9-1	Challenges or Threats to Fill-and-Finish Contract Manufacturing	5-76

Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2018

LIST OF FIGURES

Chapter 1

1.2-A	Size of the Worldwide Biopharmaceutical Fill-and-Finish Contract Manufacturing Market in US\$B	1-5
1.3-A	Respondents' Biopharmaceutical Products by Phase	1-6
1.3-B	Number of Products Outsourced by Dosage Form: 2018–2023	1-6
1.3-C	Simple Average Percentages of Expected Overall Outsourcing Budget	1-9
1.4-A	Percentage of Fill Lines Among Contractor Respondents for Various Dosage Forms	1-10
1.4-B	Capacity Expansion Plans	1-11
1.4-C	Annual Growth Rates: Industry Estimate versus Company Forecast	1-13
1.4-D	Breakout of Contracting Business by Product Type: 2018 and 2020	1-14

Chapter 2

2.4-A	Explanation of Box-and-Whiskers Plot	2-5
-------	--------------------------------------	-----

Chapter 3

3.2-A	Percentage of Fill Lines Available Among Contractor Respondents for Various Dosage Forms	3-6
3.3-A	Respondents' Biopharmaceutical Products by Phase	3-8
3.3-B	Percentage of Products Outsourced: 2018	3-9
3.3-C	Simple Average Percentages of Expected Overall Outsourcing Budget	3-10
3.3-D	Number of Products Outsourced by Dosage Form: 2018–2023	3-11
3.6-A	Size of the Worldwide Biopharmaceutical Fill-and-Finish Contract Manufacturing Market in US\$B	3-15
3.7-A	Preference for Single-Service CMOs Split by Trend	3-17

Chapter 4

4.1-A	Respondent Locations	4-3
4.1-B	In-House Fill-and-Finish Manufacturing Capability	4-4
4.2-A	Summation of Outsourced Units Required: Vials	4-12
4.2-B	Summation of Outsourced Units Required: Syringes	4-12
4.2-C	Percentage of Products Outsourced: 2018	4-13
4.2-D	SafeBridge® Category Requirements	4-15
4.2-E	Respondents' Biopharmaceutical Products Produced by Dosage Form	4-17
4.2-F	Respondents' Biopharmaceutical Products by Phase	4-17
4.2-G	Respondents' Biopharmaceutical Products by Company Type	4-18
4.3-A	Format Used for Drug Product Launch	4-20
4.3-B	Importance of Device Development	4-22

Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2018

LIST OF FIGURES (continued)

Chapter 4

4.4-A	Respondents' Special Handling Requirements	4-48
4.4-B	Distribution of Percentage of Products with Special Handling Needs	4-49
4.4-C	Special Handling Needs Required	4-49
4.4-D	Distribution of Average Fill-and-Finish Yield Loss	4-52
4.5-A	Distribution of Respondents with In-House Capacity	4-56
4.5-B	Changes to In-House Filling Capacity for Respondents with In-House Capability	4-60
4.5-C	Fill-and-Finish Importance to Drug Product Portfolio	4-62
4.5-D	Outsourcing Focus Areas	4-66
4.6-A	Views on Areas Underserved by Fill-and-Finish CMOs	4-72
4.7-A	Preference for One-Stop-Shop CMO	4-83
4.7-B	Capital Investment's Impact on Outsourcing Decisions	4-99
4.8-A	Price Change Over Last Two Years: User Respondents	4-110
4.8-B	Different Price Model Used for Commercial Products	4-112
4.9-A	Average Per-Batch Price by Product Phase by Product Type	4-116
4.9-B	Unit Price versus Batch Size: Non-Lyophilized	4-117
4.9-C	Unit Price versus Batch Size: Lyophilized	4-117
4.9-D	Price Per-Batch by SafeBridge® Level: Non-Lyophilized	4-118
4.9-E	Price Per-Batch by SafeBridge® Level: Small Batch Size	4-119
4.9-F	Average Fill-and-Finish Outsourcing Budgets by Respondent Type	4-122
4.9-G	Simple Average: Percentage of F&F Outsourcing Budget by Service: 2018	4-124
4.9-H	Weighted Average: Percentage of F&F Outsourcing Budget by Service 2018	4-126
4.10-A	Satisfaction with CMOs' Troubleshooting Capability	4-127
4.11-A	Split Between One-Stop-Shop CMOs versus Single-Service CMOs	4-146
4.11-B	Comparison of Outsourcing Trend Segmented by Company Type	4-146
4.11-C	Preference for Single-Service CMOs Split by Trend	4-148

Chapter 5

5.1-A	Number of Years Fill-and-Finish Services Offered	5-2
5.2-A	Percentage of Fill Lines Among Contractor Respondents for Various Dosage Forms	5-8
5.2-B	Capacity Expansion Plans	5-11
5.3-A	Breakout of Contracting Business by Product Type: 2018 and 2020	5-14
5.3-B	Fill Line Capacity Utilization Rates	5-15
5.3-C	Lyophilization Capacity Utilization Rates	5-16
5.3-D	Average Number of Batches Ran per Fill Line in 2017	5-18
5.3-E	Average Batch Size Ran by Fill Line in 2017	5-20
5.4-A	Fill versus Finish Capabilities	5-23
5.4-B	Average Yield Loss	5-28

Biopharmaceutical Contract Fill-and-Finish: Best Practices Study 2018

LIST OF FIGURES (continued)

Chapter 5

5.5-A	Importance of Device Development	5-33
5.5-B	Fill-and-Finish Investment Areas	5-36
5.5-C	Specialized Equipment Investments	5-39
5.5-D	New Technologies or Capabilities Needed	5-40
5.6-A	Price Change Over Last Two Years: CMO Respondents	5-43
5.6-B	Price Change Over Last Two Years: CMO and User Comparison	5-44
5.6-C	Pricing Methods	5-45
5.6-D	Use of Different Pricing Methods Based on Product Phase	5-46
5.6-E	Batch Size	5-48
5.6-F	Batch Pricing	5-49
5.6-G	Unit Prices versus Batch Size	5-49
5.6-H	Average Targeted and Achieved Gross Profit Margins	5-51
5.7-A	Multi-Molecule Agreements in Place	5-54
5.7-B	Aggregate Liability Limits	5-57
5.7-C	Batch Liability Offering for High-Cost API	5-59
5.8-A	Average Annual Growth Rates: Industry Estimate versus Company Forecast	5-66
5.8-B	Expected Service Mix Revenue by Contractor Type: 2018	5-68
5.8-C	Expected Revenue by Product Phase: 2018	5-70
5.8-D	Expected Revenue Contribution by Customer Type	5-72
5.8-E	Expected Percentage of Business from World Regions	5-74
5.9-A	Challenges or Threats to Fill-and-Finish Contract Manufacturing	5-75
5.9-B	One-Stop-Shop Outsourcing Trends	5-79